Lambert-Eaton Myasthenic Syndrome; Pathogenesis, Diagnosis, and Therapy
Author
Source
Issue
Vol. 2011, Issue 2011 (31 Dec. 2011), pp.1-5, 5 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2011-09-29
Country of Publication
Egypt
No. of Pages
5
Main Subjects
Abstract EN
Lambert-Eaton Myasthenic Syndrome (LEMS) is a rare disease with a well-characterized pathogenesis.
In 50% of the patients, LEMS is a paraneoplastic manifestation and caused by a small cell lung carcinoma (SCLC).
Both LEMS patients with SCLC and those without this tumour have in 85% of cases pathogenetic antibodies of very high LEMS specificity against voltage-gated calcium channels (VGCCs) in the cell membrane of the presynaptic motor nerve terminal.
Better understanding of LEMS pathogenesis has lead to targeted symptomatic therapy aimed at the neuromuscular junction and to semispecific immuno-suppression.
For SCLC LEMS, tumour therapy is essential.
American Psychological Association (APA)
Gilhus, Nils Erik. 2011. Lambert-Eaton Myasthenic Syndrome; Pathogenesis, Diagnosis, and Therapy. Autoimmune Diseases،Vol. 2011, no. 2011, pp.1-5.
https://search.emarefa.net/detail/BIM-512703
Modern Language Association (MLA)
Gilhus, Nils Erik. Lambert-Eaton Myasthenic Syndrome; Pathogenesis, Diagnosis, and Therapy. Autoimmune Diseases No. 2011 (2011), pp.1-5.
https://search.emarefa.net/detail/BIM-512703
American Medical Association (AMA)
Gilhus, Nils Erik. Lambert-Eaton Myasthenic Syndrome; Pathogenesis, Diagnosis, and Therapy. Autoimmune Diseases. 2011. Vol. 2011, no. 2011, pp.1-5.
https://search.emarefa.net/detail/BIM-512703
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-512703